Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to -$5.4 million.

  • Arcturus Therapeutics Holdings' Change in Accured Expenses fell 6636.98% to -$5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.2 million, marking a year-over-year decrease of 69177.16%. This contributed to the annual value of $5.9 million for FY2024, which is 110884.35% up from last year.
  • Per Arcturus Therapeutics Holdings' latest filing, its Change in Accured Expenses stood at -$5.4 million for Q3 2025, which was down 6636.98% from -$6.1 million recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' Change in Accured Expenses' 5-year high stood at $10.6 million during Q2 2021, with a 5-year trough of -$9.4 million in Q4 2021.
  • Moreover, its 5-year median value for Change in Accured Expenses was -$454000.0 (2023), whereas its average is -$41947.4.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first skyrocketed by 46508.28% in 2021, then plummeted by 217465.75% in 2025.
  • Arcturus Therapeutics Holdings' Change in Accured Expenses (Quarter) stood at -$9.4 million in 2021, then surged by 178.73% to $7.4 million in 2022, then plummeted by 61.65% to $2.8 million in 2023, then soared by 130.15% to $6.6 million in 2024, then crashed by 182.61% to -$5.4 million in 2025.
  • Its Change in Accured Expenses was -$5.4 million in Q3 2025, compared to -$6.1 million in Q2 2025 and -$8.2 million in Q1 2025.